Format

Send to

Choose Destination
Curr Pharm Biotechnol. 2011 Dec;12(12):2158-64.

Transforming growth factor beta in pancreatic cancer.

Author information

1
Universitätsklinikum Münster, Hämotology & Onkologie, Münster, Albert-Schweitzer-Str. 33, Germany. andreas.hilbig@ukmuenster.de

Abstract

Pancreatic cancer has high incidence and mortality rates, and effective treatment remains a clinical challenge. As deregulation of the cytokine transforming growth factor beta (TGF-β) contributes to the progression of pancreatic carcinoma, the TGF-β pathway has been targeted using various strategies, including small molecule inhibitors of TGF-βRI, TGF-β-specific neutralizing antibodies and antisense compounds. As increased TGF-β2 levels in serum or tumor tissue of patients with pancreatic cancer correlated with poor prognosis, inhibition of TGF-β2 synthesis via the antisense oligonucleotide trabedersen (AP 12009) is a promising approach.

PMID:
21619533
DOI:
10.2174/138920111798808356
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center